Published online Mar 27, 2023. doi: 10.4240/wjgs.v15.i3.420
Peer-review started: January 20, 2023
First decision: February 10, 2023
Revised: February 16, 2023
Accepted: March 3, 2023
Article in press: March 3, 2023
Published online: March 27, 2023
Processing time: 66 Days and 8 Hours
Emerging studies indicate the critical involvement of microorganisms, such as Epstein-Barr virus (EBV), in the pathogenesis of inflammatory bowel disease (IBD). Immunosuppressive therapies for IBD can reactivate latent EBV, complicating the clinical course of IBD.
This study explored the clinical significance of EBV expression in B lymphocytes derived from IBD patients’ intestinal tissues in detail.
This study aimed to explore the clinical significance of latent EBV infection in IBD patients.
Double staining for EBV encoded RNA and CD20 to determine latent EBV infection. The clinic-pathological data were analyzed between the two different latent EBV groups and also between the mild-to-moderate and severe disease groups.
Systolic pressure, variety of disease, the severity of illness, and pre-op corticosteroids were significantly different between the EBV-negative and EBV-positive groups. Systolic pressure, variety of disease, pre-op corticosteroids and EBV infection were significantly different between the mild-to-moderate and severe disease groups.
Latent EBV infection is positively related to severity of IBD illness.
The role of EBV in IBD development should be further investigated; latent EBV infection in patients with serious IBD should be closely monitored.